Human CD255 Antibody from MYBIOSOURCE INC.

Search, find, compare suppliers for anti-Human CD255 antibody, protein, ELISA kits.

Edit 
Antigenic SpecificityHuman CD255
Clone[4ACARL-2]
Host SpeciesMouse
Reactive Specieshuman
IsotypeIgG3
Formatunconjugated
Size100 tests, 500 tests
Concentrationn/a
ApplicationsFlow Cytometry (FC/FACS), ELISA Capture (EIA), Neutralization
Reviews / RatingsIf you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY.
DescriptionTNF-like weak inducer of apoptosis (TWEAK) is a type II transmembrane TNF superfamily member with strong homology to TNF in its extracellular portion, though less potent in inducing apoptosis. It has been clustered as CD255. TWEAK transcript is expressed broadly in many adult and fetal tissues; however, the staining of human peripheral blood mononuclear cells with TWEAK-specific antibodies shows a more restricted pattern. TWEAK is expressed as membrane-bound and secreted forms. Interaction of TWEAK with its receptors (DR3, Fn14) promotes secretion of IL-8, activation of NF-kappaB, proliferation of endothelial cells, and apoptosis in a number of human cell lines. The 4ACARL-2 antibody can neutralize the bioactivity of natural or recombinant
Immunogenn/a
Other Namesn/a
Gene, Accession #[CD255]
Catalog #MBS8501532
Price$280, $350
Order / More InfoHuman CD255 Antibody from MYBIOSOURCE INC.
Product Specific References1. Fitzgerald, K., et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego. 2. Chicheportiche, Y., et al. 1997. J. Biol. Chem. 272:32401. 3. Kaplan, M., et al. 2000. J. Immunol. 164:2897. 4. Saas, P., et al. 2000. Glia 32:102. 5. Wiley, S., et al. 2001. Immunity 15:837.
MYBIOSOURCE INC.
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166

sales@mybiosource.com

http://www.MyBioSource.com

Profile of MYBIOSOURCE INC.
Return to Antibodies

© 1980 - 2024 Linscott's Directory, Linscott's USA. All rights reserved.